Movement Alert|GIANT BIOGENE Declines 5.51% in Regular Trading, HK Personal Products Sector Faces Broad Selloff on Peer Profit Warning

Market Focus08-18

On August 18, GIANT BIOGENE fell 5.51% in regular trading, trading at HK$28.28/share, with turnover of HK$49.84 million. The decline came amid a broad selloff in Hong Kong-listed new consumer and personal care stocks.

On the news front, peer company Shanghai Jahwa (Upper Beauty) plunged over 28% after warning that its interim profit would decline 76.6%-78.4%, sparking market concerns over the earnings outlook for the beauty and skincare sector. GIANT BIOGENE was simultaneously scheduled to hold a board meeting on the same day to review its interim results for the six months ended June 30, creating a dual overhang of sector-wide sentiment pressure and its own earnings disclosure window.

For context, the company previously reported annual revenue of RMB 5.519 billion for fiscal year ended December 2025, down 0.4% year-over-year, with net profit declining 7.1%. Within the Personal Products sector, CHICMAX fell 29.2%, MAO GEPING fell 3.43%, HENGAN INT'L fell 1.48%, and BUTONG GROUP fell 1.35%, reflecting widespread sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment